Literature DB >> 12215448

Transition of arrestin into the active receptor-binding state requires an extended interdomain hinge.

Sergey A Vishnivetskiy1, Joel A Hirsch, Maria-Gabriela Velez, Yulia V Gurevich, Vsevolod V Gurevich.   

Abstract

Arrestins selectively bind to the phosphorylated activated form of G protein-coupled receptors, thereby blocking further G protein activation. Structurally, arrestins consist of two domains topologically connected by a 12-residue long loop, which we term the "hinge" region. Both domains contain receptor-binding elements. The relative size and shape of arrestin and rhodopsin suggest that dramatic changes in arrestin conformation are required to bring all of its receptor-binding elements in contact with the cytoplasmic surface of the receptor. Here we use the visual arrestin/rhodopsin system to test the hypothesis that the transition of arrestin into its active receptor-binding state involves a movement of the two domains relative to each other that might be limited by the length of the hinge. We have introduced three insertions and 24 deletions in the hinge region and measured the binding of all of these mutants to light-activated phosphorylated (P-Rh*), dark phosphorylated (P-Rh), dark unphosphorylated (Rh), and light-activated unphosphorylated rhodopsin (Rh*). The addition of 1-3 extra residues to the hinge has no effect on arrestin function. In contrast, sequential elimination of 1-8 residues results in a progressive decrease in P-Rh* binding without changing arrestin selectivity for P-Rh*. These results suggest that there is a minimum length of the hinge region necessary for high affinity binding, consistent with the idea that the two domains move relative to each other in the process of arrestin transition into its active receptor-binding state. The same length of the hinge is also necessary for the binding of "constitutively active" arrestin mutants to P-Rh*, dark P-Rh, and Rh*, suggesting that the active (receptor-bound) arrestin conformation is essentially the same in both wild type and mutant forms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215448     DOI: 10.1074/jbc.M206951200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

Review 1.  Synthetic biology with surgical precision: targeted reengineering of signaling proteins.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Cell Signal       Date:  2012-06-01       Impact factor: 4.315

Review 2.  Extensive shape shifting underlies functional versatility of arrestins.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Curr Opin Cell Biol       Date:  2013-11-16       Impact factor: 8.382

3.  Role of receptor-attached phosphates in binding of visual and non-visual arrestins to G protein-coupled receptors.

Authors:  Luis E Gimenez; Seunghyi Kook; Sergey A Vishnivetskiy; M Rafiuddin Ahmed; Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

4.  Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET.

Authors:  Pascale G Charest; Sonia Terrillon; Michel Bouvier
Journal:  EMBO Rep       Date:  2005-04       Impact factor: 8.807

5.  The differential engagement of arrestin surface charges by the various functional forms of the receptor.

Authors:  Susan M Hanson; Vsevolod V Gurevich
Journal:  J Biol Chem       Date:  2005-12-08       Impact factor: 5.157

6.  Visual and both non-visual arrestins in their "inactive" conformation bind JNK3 and Mdm2 and relocalize them from the nucleus to the cytoplasm.

Authors:  Xiufeng Song; Dayanidhi Raman; Eugenia V Gurevich; Sergey A Vishnivetskiy; Vsevolod V Gurevich
Journal:  J Biol Chem       Date:  2006-05-31       Impact factor: 5.157

7.  Arrestin mobilizes signaling proteins to the cytoskeleton and redirects their activity.

Authors:  Susan M Hanson; Whitney M Cleghorn; Derek J Francis; Sergey A Vishnivetskiy; Dayanidhi Raman; Xiufeng Song; K Saidas Nair; Vladlen Z Slepak; Candice S Klug; Vsevolod V Gurevich
Journal:  J Mol Biol       Date:  2007-02-22       Impact factor: 5.469

Review 8.  The emerging roles of β-arrestins in fibrotic diseases.

Authors:  Yuan-jing Gu; Wu-yi Sun; Sen Zhang; Jing-jing Wu; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-09-21       Impact factor: 6.150

9.  Conformation of receptor-bound visual arrestin.

Authors:  Miyeon Kim; Sergey A Vishnivetskiy; Ned Van Eps; Nathan S Alexander; Whitney M Cleghorn; Xuanzhi Zhan; Susan M Hanson; Takefumi Morizumi; Oliver P Ernst; Jens Meiler; Vsevolod V Gurevich; Wayne L Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

10.  Engineering visual arrestin-1 with special functional characteristics.

Authors:  Sergey A Vishnivetskiy; Qiuyan Chen; Maria C Palazzo; Evan K Brooks; Christian Altenbach; Tina M Iverson; Wayne L Hubbell; Vsevolod V Gurevich
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.